Company officials estimate about 115 million people in the United States ages 50 and older are eligible for the vaccine. Shingles, a painful condition that causes blisters, occurs when the chickenpox virus resurfaces decades later. There are an estimated 1 million cases of shingles each year in the United States; the risk of the disease increases as people age.
“All I want for Christmas is for my pharmacy to get some Shingrix,” tweeted one woman this week.
Consumers have been searching for pharmacies with Shingrix doses on neighborhood listservs, in postings on social media, and in visits to pharmacy after pharmacy. A Pennsylvania man wrote on Facebook a week ago that his wife was told by her local supermarket pharmacy that the waiting list was about 12 months. A CVS pharmacist in Gaithersburg, Md., and a Walgreens pharmacist in downtown Washington said this week that they hadn’t received any shipments since August.
“It’s worse now,” said a pharmacist at Walgreens, who declined to give her name because she wasn’t authorized to speak to reporters. The pharmacy is not keeping a waiting list because “there’s no promise of when it’s going to come out again.”
“As soon as they get it in, it’s going out pretty quick,” said Michael Rothholz, chief strategy officer for the American Pharmacists Association.
Sean Clements, a spokesman for GSK, said the manufacturer has increased supply of Shingrix in the United States, shipping “large volumes” every two to three weeks. Starting in December, Clements said the company will move to a twice-monthly shipping schedule. He declined to provide specifics. The GSK representative said 300,000 doses were shipped in November, and another 160,000 doses were shipped Dec. 3.
GSK makes Shingrix at a facility in Rixensart, Belgium, which is already at maximum capacity, said a company customer service representative. It takes six to nine months to produce the vaccine. Although certain elements were produced before the vaccine received approval from the Food and Drug Administration, the company is still playing catch-up, officials said during a briefing on their latest quarterly report.
“We need to get the supply expanded as fast as possible because we can pretty much sell anything that we make now in the U.S.,” said Luke Miels, president of GSK’s global pharmaceuticals division, during the earnings call.
U.S. pharmacies began offering the vaccine broadly in mid-March. By May, the Centers for Disease Control and Prevention was reporting shortages. Since the spring, drugstore chain CVS has had difficulty keeping an ample supply across the chain’s 9,800 stores and more than 1,100 clinics because of limited supply from the manufacturer, said spokeswoman Amy Lanctot.
Shipments arrive about every three weeks, she said. The supply “did get a little better in the fall,” she said. But since then, it has gotten worse, she said. “It’s just not being made in the amounts that are needed.”
Complicating the situation is the recommendation for consumers to get their second dose within two to six months of the first. Many consumers are struggling to find their second dose. Pharmacies are supposed to give priority to those patients. Some pharmacies are requiring consumers to get their second dose at the same place they got their first shot. Others will give the second shot if consumers show proof they have gotten the first one, regardless of where. GSK said preliminary data show that more than 70 percent of people have completed the series.
Consumers are understandably confused.
A woman who got her first shot in Delray Beach, Fla., in August was searching for her second in Brooklyn this week. “None to be found anywhere,” she tweeted.
The CDC says patients who wait longer than six months don’t have to start over. But they should get the second dose as soon as possible because the maximum immunity — more than 90 percent — is based on two doses. Protection stays above 85 percent for at least the first four years after vaccination, the CDC says. GSK did not study how much immunity is provided by one dose.
Shingrix is covered by most insurance drug plans, including Medicare Part D. The out-of-pocket cost will depend on the specific plan. The vaccine’s wholesale price is $140 per dose, but patients without insurance coverage will be paying more than that, sometimes as high as $200 or more for each shot after administration fees are added.
Consumers who have gotten the shots, which is given in the muscle of the upper arm, like the annual flu vaccine, say the side effects have included pain, soreness and swelling at the injection site for two to three days, muscle aches and flulike symptoms, headaches and upset stomach. But those side effects pale in comparison to one of the most common and serious complications of shingles, debilitating nerve pain that has no treatment or cure.
GSK directs consumers to its Shingrix locator, but the information is refreshed only once a week. Consumers are urged to contact health-care providers or pharmacies directly for the most up-to-date availability. At CVS, consumers can call pharmacies directly, but not the MinuteClinics, which are separate operations.
Acknowledging growing consumer frustration, CVS in recent weeks gave operators at the MinuteClinic’s patient support center access to the system that allows them to look up Shingrix supply at individual clinics. But the website does not mention the shortage or inform consumers they can use the toll-free number to look up supply at individual clinics. The Washington Post asked the operator to check availability at 13 clinics within 10 miles of a suburban Maryland Zip code. None had it.
As of Oct. 1, almost 7 million doses of the vaccine had been administered worldwide since the vaccine’s launch in November 2017, with most of it going to the United States. GSK said it distributed as many doses in the third quarter of 2018 as it had in the first six months of the year.
Next year, the company plans to bring “significantly more doses to the United States,” spokesman Clements said. But because health-care professionals will continue to vaccinate at a rate many times that of previous years, the company expects “ordering limits to continue throughout 2019,” he said.
Over the next two to three years, company officials said, they plan to increase production of annual doses in the “high-teens millions.”
Shingrix has been so successful that GSK executives revised their earlier annual revenue forecast for Shingrix this year from $600 million to between $900 million and nearly $1 billion, according to GSK’s latest earnings report.
Alice Crites contributed to this story.